Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | CDA | P32320 | 1/20 | 0.44 |
| ▸ | P2RY6 | Q15077 | 3/20 | 0.42 |
| ▸ | P2RY2 | P41231 | 2/20 | 0.42 |
| ▸ | P2RY4 | P51582 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
| ▸ | MTOR | P42345 | 1/20 | 0.40 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.40 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.40 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.40 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.39 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.39 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.39 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.39 |
| ▸ | ADK | P55263 | 4/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21665429 | 1.00 | MAPT (0.44) | MAPTCDAP2RY6P2RY2P2RY4 | |
| SCHEMBL21665273 | 0.90 | P2RY6 (0.51) | P2RY6P2RY2P2RY4 | |
| SCHEMBL20013790 | 0.90 | P2RY6 (0.51) | P2RY6P2RY2P2RY4 | |
| SCHEMBL20013387 | 0.89 | MAPT (0.46) | MAPTCDAP2RY6LMNATHRB | |
| SCHEMBL20013409 | 0.89 | MAPT (0.46) | MAPTCDAP2RY6LMNATHRB | |
| SCHEMBL20013543 | 0.87 | P2RY6 (0.60) | P2RY6P2RY2P2RY4 | |
| SCHEMBL20013405 | 0.87 | MAPT (0.46) | MAPTCDAP2RY6LMNATHRB | |
| SCHEMBL20013395 | 0.87 | MAPT (0.46) | MAPTCDAP2RY6LMNATHRB | |
| SCHEMBL20013399 | 0.87 | MAPT (0.46) | MAPTCDAP2RY6LMNATHRB | |
| SCHEMBL21665434 | 0.86 | P2RY6 (0.59) | P2RY6P2RY2P2RY4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200040025-A1 | URIDINE NUCLEOSIDE DERIVATIVES, COMPOSITIONS AND METHODS OF USE | TUFTS UNIVERSITY | 2020-02-06 | — | — | US | disclosed |
| WO-2018058148-A1 | URIDINE NUCLEOSIDE DERIVATIVES, COMPOSITIONS AND METHODS OF USE | TUFTS UNIVERSITY (US) | 2018-03-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200040025-A1 | URIDINE NUCLEOSIDE DERIVATIVES, COMPOSITIONS AND METHODS OF USE | P2RY6, UPP1, UMPS | MAPT 201/4885CDA 575/4885P2RY6 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.